225385-07-9 Usage
Uses
Used in Pharmaceutical Industry:
4-chloro-2-methyl-6-phenylthieno[3,2-d]pyrimidine is used as a research compound for its potential therapeutic applications in the treatment of various diseases. Its unique chemical structure and properties make it a valuable target for further research and development in the pharmaceutical industry.
Used in Cancer Treatment:
In the field of oncology, 4-chloro-2-methyl-6-phenylthieno[3,2-d]pyrimidine is used as a potential anticancer agent. It has shown promising biological activities that warrant further investigation into its efficacy in treating different types of cancer.
Used in Inflammatory Disorders:
4-chloro-2-methyl-6-phenylthieno[3,2-d]pyrimidine is also being studied for its potential use in the treatment of inflammatory disorders. Its biological activities suggest that it may have therapeutic benefits in managing inflammation-related conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 225385-07-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,5,3,8 and 5 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 225385-07:
(8*2)+(7*2)+(6*5)+(5*3)+(4*8)+(3*5)+(2*0)+(1*7)=129
129 % 10 = 9
So 225385-07-9 is a valid CAS Registry Number.
225385-07-9Relevant academic research and scientific papers
Structure-activity relationships of a series of pyrrolo[3,2-d]pyrimidine derivatives and related compounds as neuropeptide Y5 receptor antagonists
Norman,Chen,Chen,Fotsch,Hale,Han,Hurt,Jenkins,Kincaid,Liu,Lu,Moreno,Santora,Sonnenberg,Karbon
, p. 4288 - 4312 (2007/10/03)
Neuropeptide Y (NPY) has been shown to play an important role in the regulation of food intake and energy balance. Pharmacological data suggests that the Y5 receptor subtype contributes to the effects of NPY on appetite, and therefore a Y5 antagonist might be a useful therapeutic agent for the treatment of obesity. In attempts to identify potential Y5 antagonists, a series of pyrrolo[3,2-d]pyrimidine derivatives was prepared and evaluated for their ability to bind to Y5 receptors in vitro. We report here the synthesis and initial structure-activity relationship investigations for this class of compounds. The target compounds were prepared by a variety of synthetic routes designed to modify both the substitution and the heterocyclic core of the pyrrolo[3,2-d]pyrimidine lead 1. In addition to identifying several potent Y5 antagonists for evaluation as potential antiobesity agents, a pharmacophore model for the human Y5 receptor is presented.
